Perspectives on prostate cancer diagnosis and treatment: A roundtable Journal Article


Authors: Brawer, M. K.; Stamey, T. A.; Fowler, J.; Droller, M.; Messing, E.; Fair, W. R.
Article Title: Perspectives on prostate cancer diagnosis and treatment: A roundtable
Abstract: This roundtable was held September 30, 2000. It addressed, first of all, the accuracy and proper interpretation of the available prostate-specific antigen assays. Dr. Brawer presented data to demonstrate the specificity of the complexed prostate-specific antigen assay. Dr. Stamey counterpoised evidence that pretreatment prostate-specific antigen levels less than 9 ng/mL are attributable to benign prostatic hyperplasia and therefore are of little value as an indicator of when to initiate treatment for prostate cancer. The other roundtable participants offered reviews and new data regarding hormonal therapy as primary or adjunctive treatment of prostate cancer. Dr. Fowler presented a large retrospective series of men with locally advanced prostate cancer for whom androgen ablation was the primary therapy. Dr. Droller discussed his center's experience in integrating hormonal therapy with brachytherapy. Finally, Dr. Messing reviewed and critiqued the evidence that the combination of hormonal and radiation therapy improves survival. © 2001, Elsevier Science Inc.
Keywords: cancer survival; treatment outcome; aged; survival analysis; androgen; review; advanced cancer; cancer growth; cancer adjuvant therapy; cancer radiotherapy; combined modality therapy; follow up; cancer diagnosis; neoplasm staging; diagnostic accuracy; sensitivity and specificity; treatment indication; prostate specific antigen; reproducibility of results; diagnostic procedure; quality of life; tumor markers, biological; cancer hormone therapy; prostate-specific antigen; prostatic neoplasms; antigen specificity; diagnostic value; prostatectomy; predictive value of tests; brachytherapy; diethylstilbestrol; prostate hypertrophy; gonadorelin agonist; orchiectomy; diagnostic test; hormone; androgens; prostate carcinoma; blood level; humans; human; male; priority journal
Journal Title: Urology
Volume: 58
Issue: 2
ISSN: 0090-4295
Publisher: Elsevier Science, Inc.  
Date Published: 2001-08-01
Start Page: 135
End Page: 140
Language: English
DOI: 10.1016/s0090-4295(01)01178-5
PUBMED: 11489681
PROVIDER: scopus
DOI/URL:
Notes: Export Date: 21 May 2015 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. William R Fair
    342 Fair